HNSCC
MCID: SQM013
MIFTS: 82

Squamous Cell Carcinoma, Head and Neck (HNSCC)

Categories: Cancer diseases, Gastrointestinal diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Squamous Cell Carcinoma, Head and Neck

MalaCards integrated aliases for Squamous Cell Carcinoma, Head and Neck:

Name: Squamous Cell Carcinoma, Head and Neck 58 13
Squamous Cell Carcinoma of the Head and Neck 39 12 54 26 76 30 6 15 74
Head and Neck Squamous Cell Carcinoma 12 54 26 15 17
Hnscc 58 54 26 76 56
Carcinoma, Squamous Cell of Head and Neck 77 54
Head and Neck Cancer 54 44
Squamous Cell Carcinoma of the Nasal Cavity and Paranasal Sinuses 60
Squamous Cell Carcinoma of the Nasal Cavity and Sinuses 60
Squamous Cell Carcinoma, Head and Neck, Somatic 58
Squamous Cell Carcinoma of the Hypopharynx 60
Squamous Cell Carcinoma of Salivary Glands 60
Squamous Cell Carcinomas of Head and Neck 12
Squamous Cell Carcinoma of the Oropharynx 60
Carcinoma, Squamous Cell, Head and Neck 41
Salivary Gland Squamous Cell Carcinoma 17
Squamous Cell Carcinoma of the Larynx 60
Squamous Cell Carcinoma of the Lip 60
Carcinoma of the Head and Neck 12
Squamous Cell Carcinoma of Lip 74
Lip Squamous Cell Carcinoma 56
Cancer of Head and Neck 74
Cancer, Head/neck 41
Scchn 26

Characteristics:

OMIM:

58
Inheritance:
autosomal recessive


HPO:

33
squamous cell carcinoma, head and neck:
Inheritance autosomal recessive inheritance


Classifications:



Summaries for Squamous Cell Carcinoma, Head and Neck

MedlinePlus : 44 Head and neck cancer includes cancers of the mouth, nose, sinuses, salivary glands, throat, and lymph nodes in the neck. Most begin in the moist tissues that line the mouth, nose, and throat. Symptoms include A lump or sore that does not heal A sore throat that does not go away Trouble swallowing A change or hoarseness in the voice Head and neck cancers are twice as common in men. Using tobacco or alcohol increases your risk. In fact, around 75 percent of head and neck cancers are linked to tobacco use, including smoking and smokeless tobacco. Infection with HPV is a risk factor for some head and neck cancers. To diagnose head and neck cancer, your doctor will do a physical exam and diagnostic tests. You will have a biopsy, where a sample of tissue is taken out and examined under a microscope. It is the only test that can tell for sure if you have cancer. If found early, these cancers are often curable. Treatments may include surgery, radiation therapy, chemotherapy, or a combination. Treatments can affect eating, speaking or even breathing, so patients may need rehabilitation. NIH: National Cancer Institute

MalaCards based summary : Squamous Cell Carcinoma, Head and Neck, also known as squamous cell carcinoma of the head and neck, is related to tongue squamous cell carcinoma and squamous cell carcinoma, and has symptoms including tinnitus, snoring and sore throat. An important gene associated with Squamous Cell Carcinoma, Head and Neck is ING1 (Inhibitor Of Growth Family Member 1), and among its related pathways/superpathways are ERK Signaling and PEDF Induced Signaling. The drugs Fluorouracil and Cetuximab have been mentioned in the context of this disorder. Affiliated tissues include skin, lymph node and salivary gland, and related phenotypes are squamous cell carcinoma and Increased shRNA abundance (Z-score > 2)

Disease Ontology : 12 A head and neck carcinoma that has material basis in squamous cells that line the moist, mucosal surfaces inside the head and neck.

Genetics Home Reference : 26 Squamous cell carcinoma is a cancer that arises from particular cells called squamous cells. Squamous cells are found in the outer layer of skin and in the mucous membranes, which are the moist tissues that line body cavities such as the airways and intestines. Head and neck squamous cell carcinoma (HNSCC) develops in the mucous membranes of the mouth, nose, and throat.

NIH Rare Diseases : 54 Cancers that are known collectively as head and neck cancers usually begin in the squamous cells that line the moist, mucosal surfaces inside the head and neck (for example, inside the mouth, the nose, and the throat). These squamous cell cancers are often referred to as squamous cell carcinomas of the head and neck. At least 75 % of head and neck cancers are caused by tobacco and alcohol use. Infection with cancer-causing types of human papillomavirus (HPV), especially HPV-16, is a risk factor for some types of head and neck cancers. The symptoms of head and neck cancers may include a lump or a sore that does not heal, a sore throat that does not go away, difficulty in swallowing, and a change or hoarseness in the voice. Treatment for head and neck cancer can include surgery, radiation therapy, chemotherapy, targeted therapy, or a combination of treatments.

UniProtKB/Swiss-Prot : 76 Squamous cell carcinoma of the head and neck: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes.

Wikipedia : 77 Squamous cell carcinomas (SCCs), also known as epidermoid carcinomas, comprise a number of different... more...

Description from OMIM: 275355

Related Diseases for Squamous Cell Carcinoma, Head and Neck

Diseases related to Squamous Cell Carcinoma, Head and Neck via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 437)
# Related Disease Score Top Affiliating Genes
1 tongue squamous cell carcinoma 32.8 AKT1 MIR21 TP53
2 squamous cell carcinoma 32.2 AKT1 BRAF FGFR3 H19 HRAS ING1
3 breast cancer 31.8 AKT1 BRAF GNAS H19 HRAS ING1
4 thyroid cancer 31.7 AKT1 BRAF GNAS H19 HRAS PIK3CA
5 colorectal cancer 31.6 AKT1 BRAF FGFR3 GNAS H19 HRAS
6 small cell cancer of the lung 31.6 AKT1 MIR21 PIK3CA PTEN TP53
7 melanoma 31.6 BRAF H19 MIR205 MIR210 PTEN TP53
8 esophageal cancer 31.6 AKT1 H19 HRAS MIR205 MIR21 PIK3CA
9 lung squamous cell carcinoma 31.5 AKT1 BRAF FGFR3 HRAS NFE2L2 PIK3CA
10 cervical cancer 31.4 AKT1 FGFR3 GNAS H19 HRAS MIR21
11 lung cancer 31.4 AKT1 BRAF FGFR3 H19 HRAS MIR205
12 adenocarcinoma 31.4 AKT1 BRAF FGFR3 GNAS H19 HRAS
13 suppression of tumorigenicity 12 31.3 AKT1 BRAF HRAS PIK3CA PTEN SMAD4
14 prostate cancer 31.3 AKT1 H19 HRAS MIR205 MIR21 MIR210
15 glioma 31.3 BRAF H19 IDH2 MIR21 MIR210 PIK3CA
16 breast adenocarcinoma 31.3 AKT1 H19 PIK3CA PTEN SMAD4 TP53
17 adenoid cystic carcinoma 31.2 AKT1 HRAS PIK3CA PTEN TP53
18 ovarian cancer 31.2 AKT1 BRAF H19 MIR21 MIR210 PIK3CA
19 nasopharyngeal carcinoma 31.2 AKT1 H19 HRAS PIK3CA TP53
20 bladder cancer 31.2 FGFR3 H19 HRAS MIR205 MIR21 TP53
21 adenoma 31.2 BRAF GNAS SMAD4 TP53
22 leukemia, chronic lymphocytic 2 31.1 BRAF HRAS TP53
23 differentiated thyroid carcinoma 31.1 BRAF HRAS TP53
24 pancreatic cancer 31.0 AKT1 H19 HRAS MIR205 MIR21 MIR210
25 oral cavity cancer 30.9 PIK3CA PTEN TNFRSF10B TP53
26 ovary adenocarcinoma 30.8 HRAS PIK3CA TP53
27 polymyositis 30.8 MIR21 MIR210
28 cheilitis glandularis 11.5
29 salivary gland carcinoma 11.4
30 salivary gland cancer, adult 11.0
31 hepatocellular carcinoma 10.9 AKT1 GNAS H19 HRAS IDH2 MIR205
32 large intestine cancer 10.9 AKT1 BRAF GNAS HRAS IDH2 PIK3CA
33 gastric adenocarcinoma 10.9 AKT1 BRAF GNAS H19 HRAS MAP2K2
34 lung cancer susceptibility 3 10.9 AKT1 BRAF FGFR3 GNAS H19 HRAS
35 cholangiocarcinoma 10.9 AKT1 BRAF H19 IDH2 MIR21 PIK3CA
36 glioblastoma 10.9 AKT1 BRAF H19 HRAS IDH2 MIR21
37 renal cell carcinoma, papillary, 1 10.8 BRAF FGFR3 HRAS NFE2L2 PIK3CA PTEN
38 gastrointestinal system cancer 10.8 AKT1 H19 HRAS PIK3CA PTEN SMAD4
39 bladder urothelial carcinoma 10.8 AKT1 BRAF FGFR3 HRAS NFE2L2 PIK3CA
40 pancreas adenocarcinoma 10.8 AKT1 GNAS HRAS MAP2K2 PIK3CA SMAD4
41 brain cancer 10.8 AKT1 BRAF HRAS IDH2 PIK3CA PTEN
42 myeloma, multiple 10.8 AKT1 BRAF FGFR3 H19 HRAS IDH2
43 endocrine gland cancer 10.8 AKT1 GNAS HRAS PTEN SMAD4 TP53
44 adamantinoma of long bones 10.8 BRAF H19 PIK3CA PTEN TNFRSF10B TP53
45 glioblastoma multiforme 10.8 AKT1 MIR21 MIR210 PIK3CA PTEN TP53
46 endometrial cancer 10.8 AKT1 BRAF H19 HRAS PIK3CA PTEN
47 respiratory system cancer 10.8 AKT1 HRAS PIK3CA PTEN TP53
48 ovarian serous cystadenocarcinoma 10.8 AKT1 BRAF HRAS PIK3CA TP53
49 testicular germ cell tumor 10.8 BRAF FGFR3 HRAS PTEN TP53
50 transitional cell carcinoma 10.8 BRAF FGFR3 HRAS PTEN TP53

Graphical network of the top 20 diseases related to Squamous Cell Carcinoma, Head and Neck:



Diseases related to Squamous Cell Carcinoma, Head and Neck

Symptoms & Phenotypes for Squamous Cell Carcinoma, Head and Neck

Human phenotypes related to Squamous Cell Carcinoma, Head and Neck:

33
# Description HPO Frequency HPO Source Accession
1 squamous cell carcinoma 33 HP:0002860

Symptoms via clinical synopsis from OMIM:

58
Lab:
beta family transforming growth factor resistance

Clinical features from OMIM:

275355

UMLS symptoms related to Squamous Cell Carcinoma, Head and Neck:


tinnitus, snoring, sore throat, coughing, vertigo/dizziness, equilibration disorder, halitosis

GenomeRNAi Phenotypes related to Squamous Cell Carcinoma, Head and Neck according to GeneCards Suite gene sharing:

27 (show all 36)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-107 10.28 SMAD4
2 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.28 SMAD4
3 Increased shRNA abundance (Z-score > 2) GR00366-A-116 10.28 PIK3CA
4 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.28 PTEN
5 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.28 PTEN
6 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.28 PIK3CA
7 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.28 AKT1 IDH2 PIK3CA PTEN
8 Increased shRNA abundance (Z-score > 2) GR00366-A-166 10.28 PIK3CA
9 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.28 PTEN
10 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.28 IDH2
11 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.28 AKT1 IDH2 PIK3CA
12 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.28 PIK3CA
13 Increased shRNA abundance (Z-score > 2) GR00366-A-195 10.28 SMAD4
14 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.28 IDH2
15 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.28 SMAD4
16 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.28 PTEN
17 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.28 SMAD4
18 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.28 AKT1 IDH2 PIK3CA PTEN SMAD4
19 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.28 SMAD4
20 Increased shRNA abundance (Z-score > 2) GR00366-A-46 10.28 SMAD4
21 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.28 PIK3CA
22 Increased shRNA abundance (Z-score > 2) GR00366-A-50 10.28 AKT1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-54 10.28 SMAD4
24 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.28 PTEN
25 Increased shRNA abundance (Z-score > 2) GR00366-A-69 10.28 IDH2
26 Increased shRNA abundance (Z-score > 2) GR00366-A-70 10.28 AKT1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.28 IDH2 SMAD4
28 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.28 SMAD4
29 Increased shRNA abundance (Z-score > 2) GR00366-A-79 10.28 AKT1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-81 10.28 SMAD4
31 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.28 AKT1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-93 10.28 PTEN
33 Decreased viability in esophageal squamous lineage GR00235-A 9.9 BRAF FGFR3 GNAS HRAS IDH2 ING1
34 Decreased cell migration GR00055-A-1 9.8 AKT1 BRAF FGFR3 HRAS MAP2K2 PIK3CA
35 Decreased sensitivity to paclitaxel GR00112-A-0 9.26 PTEN SMAD4
36 Reduced mammosphere formation GR00396-S 9.23 BRAF GNAS H19 HRAS IDH2 NFE2L2

MGI Mouse Phenotypes related to Squamous Cell Carcinoma, Head and Neck:

47 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.33 AKT1 BRAF FGFR3 GNAS HRAS ING1
2 cardiovascular system MP:0005385 10.28 AKT1 BRAF GNAS HRAS IDH2 MAP2K2
3 cellular MP:0005384 10.26 AKT1 BRAF FGFR3 GNAS ING1 MAP2K2
4 growth/size/body region MP:0005378 10.23 AKT1 BRAF FGFR3 GNAS HRAS ING1
5 homeostasis/metabolism MP:0005376 10.21 AKT1 BRAF FGFR3 GNAS HRAS ING1
6 endocrine/exocrine gland MP:0005379 10.18 AKT1 BRAF GNAS HRAS ING1 MAP2K2
7 adipose tissue MP:0005375 10.16 AKT1 BRAF GNAS MAP2K2 NFE2L2 PIK3CA
8 integument MP:0010771 10.14 AKT1 BRAF FGFR3 GNAS HRAS MAP2K2
9 neoplasm MP:0002006 10.13 AKT1 BRAF FGFR3 GNAS HRAS IDH2
10 craniofacial MP:0005382 10.11 BRAF FGFR3 GNAS HRAS MAP2K2 NFE2L2
11 digestive/alimentary MP:0005381 10.1 BRAF FGFR3 HRAS MAP2K2 NFE2L2 PTEN
12 normal MP:0002873 9.96 AKT1 BRAF FGFR3 GNAS HRAS MAP2K2
13 liver/biliary system MP:0005370 9.91 AKT1 BRAF GNAS NFE2L2 PTEN SMAD4
14 renal/urinary system MP:0005367 9.76 BRAF FGFR3 GNAS HRAS NFE2L2 PTEN
15 respiratory system MP:0005388 9.56 AKT1 BRAF FGFR3 GNAS HRAS NFE2L2
16 skeleton MP:0005390 9.36 AKT1 BRAF FGFR3 GNAS HRAS MAP2K2

Drugs & Therapeutics for Squamous Cell Carcinoma, Head and Neck

Drugs for Squamous Cell Carcinoma, Head and Neck (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 450)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-21-8 3385
2
Cetuximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 205923-56-4 56842117 2333
3
Titanium dioxide Approved Phase 4 13463-67-7
4
Ethanol Approved Phase 4,Phase 1,Not Applicable 64-17-5 702
5
mometasone furoate Approved, Investigational, Vet_approved Phase 4 83919-23-7
6
Petrolatum Approved, Investigational Phase 4 8009-03-8
7
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 143 6006
8
Cevimeline Approved Phase 4 107233-08-9 25137844 83898
9
Raltitrexed Approved, Investigational Phase 4,Phase 1 112887-68-0 104758
10
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
11 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
12 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
13 Antineoplastic Agents, Immunological Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
14 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
15 Mitomycins Phase 4,Phase 2,Not Applicable
16 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
17 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
19 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1
20 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
21 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1
22 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
23 Anti-Allergic Agents Phase 4,Phase 2
24 Cholinergic Agents Phase 4,Phase 3,Early Phase 1
25 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
26 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
27 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
28 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1
29 Folate Phase 4,Phase 3,Phase 2,Phase 1
30 Vitamin B9 Phase 4,Phase 3,Phase 2,Phase 1
31 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1
32 Muscarinic Agonists Phase 4
33
Cisplatin Approved Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 15663-27-1 2767 441203 84093
34
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
35
Citalopram Approved Phase 3 59729-33-8 2771
36
Tegafur Approved, Investigational Phase 3,Phase 2,Phase 1 17902-23-7 5386
37
Epinephrine Approved, Vet_approved Phase 3,Phase 2,Not Applicable 51-43-4 5816
38
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
39
Racepinephrine Approved Phase 3,Phase 2,Not Applicable 329-65-7 838
40
Methotrexate Approved Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
41
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
42
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 114977-28-5 148124
43
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
44
nivolumab Approved Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable 946414-94-4
45
Pembrolizumab Approved Phase 3,Phase 2,Phase 1 1374853-91-4
46
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
47
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
48
Gefitinib Approved, Investigational Phase 3,Phase 2,Phase 1 184475-35-2 123631
49
Cobalt Approved, Experimental Phase 3,Phase 2 7440-48-4 104729
50
Panitumumab Approved, Investigational Phase 3,Phase 2,Phase 1 339177-26-3 50070211

Interventional clinical trials:

(show top 50) (show all 933)
# Name Status NCT ID Phase Drugs
1 Cetuximab Compared to Mitomycin-C and 5-Fluorouracil for Locally Advanced Squamous Cell Carcinomas of the Head and Neck Unknown status NCT02015650 Phase 4 Cetuximab;Mitomycin-C/ 5-Fluorouracil
2 Mometasone Furoate Cream Reduces Acute Radiation Dermatitis in Head and Neck Squamous Cell Carcinomas' Patients Unknown status NCT02495064 Phase 4 Mometasone Furoate Cream
3 Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® (HICARE) Unknown status NCT01553032 Phase 4 Erbitux®
4 Study of the Effectiveness of Cevimeline on Oral Health in Patients With Radiation Induced Xerostomia Completed NCT00466388 Phase 4 Cevimeline
5 Stereotactic Body Radiotherapy for Head and Neck Tumors Completed NCT01344356 Phase 4
6 Radiotherapy Combine With Raltitrexed Versus Radiotherapy Alone in Older Patients With HNSCC. Recruiting NCT03196843 Phase 4 Raltitrexed
7 E10A for the Treatment of Squamous Cell Carcinoma of the Head and Neck Unknown status NCT02630264 Phase 3 Endostatins;Paclitaxel injection;Cisplatin injection
8 Double-blind, Placebo-controlled, Randomized Study of the Effectiveness of Escitalopram on Emotional Distress of Head and Neck Cancer Patients During Cancer Treatment Unknown status NCT00935675 Phase 3 Escitalopram
9 Evaluation of 3DCRT Versus IGRT and Analysis of Early Response in Head and Neck Cancer. Unknown status NCT01124409 Phase 3
10 S-1 or Tegafur-Uracil in Treating Patients With Previously Treated Stage III or Stage IV Head and Neck Cancer Unknown status NCT00336947 Phase 3 tegafur-gimeracil-oteracil potassium;tegafur-uracil
11 Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer Unknown status NCT00002659 Phase 3 cisplatin-e therapeutic implant
12 Effectiveness and Safety of INGN 201 in Combination With Chemotherapy Versus Chemotherapy Alone Unknown status NCT00041626 Phase 3
13 Study to Compare the Overall Survival of Patients Receiving INGN 201 (Study Drug) With Patients Receiving Methotrexate Unknown status NCT00041613 Phase 3
14 A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic Cancer Unknown status NCT02395016 Phase 3 nimotuzumab;Gemcitabine
15 Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer Unknown status NCT01074021 Phase 3 Nimotuzumab;placebo plus chemoradiotherapy
16 Treatment of Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck Completed NCT01086826 Phase 3 RT+CDDP/5-FU;RT+CETUXIMAB;INDUCTION CTx(TPF)+(RT+CDDP/5-FU);INDUCTION CTx(TPF)+(RT+CETUXIMAB)
17 Erlotinib,Radiation and Cisplatin in Patients With Complete Resected Squamous Cell Carcinoma of the Head and Neck Completed NCT00442455 Phase 3 Erlotinib chlorhydrate;Cisplatin
18 Cetuximab With Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects Completed NCT01012258 Phase 3
19 Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX) Completed NCT00206219 Phase 3 Gefitinib;methotrexate
20 Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Completed NCT00401323 Phase 2, Phase 3 docetaxel (XRP6976);cisplatin;5-fluorouracil (5-FU)
21 A Trial to Determine the Safety and Anti-tumor Activity Profile of the Combination of Cetuximab and Concomitant Cisplatin Plus 5-Fluorouracil (5-FU) in Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma in Head and Neck Completed NCT01177956 Phase 3 Cisplatin;5-Fluorouracil
22 Taxotere (Docetaxel) New Indication: Squamous Cell Carcinoma of the Head and Neck (SCCHN) Treatment Registration Trial Completed NCT00995293 Phase 3 DOCETAXEL;CISPLATIN;5-FLUOROURACIL
23 Cetuximab (Erbitux) in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (EXTREME) Completed NCT00122460 Phase 3 Cetuximab + Platinum (Cisplatin or Carboplatin) + 5Fluorouracil (5-FU);Platinum (Cisplatin or Carboplatin) + 5-FU
24 Fractionated Radiation Therapy in Treating Advanced Squamous Cell Carcinoma of the Head and Neck Completed NCT00771641 Phase 3
25 Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCC Completed NCT00158652 Phase 3 5FU, Paraplatin
26 DAHANCA 19: The Importance of the EGFr-inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCC Completed NCT00496652 Phase 3 Zalutumumab
27 Study of Panitumumab Efficacy in Patients With Recurrent and/or Metastatic Head and Neck Cancer Completed NCT00460265 Phase 3 ARM 2;ARM 1
28 Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers Completed NCT01166542 Phase 3 Carboplatin;Paclitaxel;Placebo
29 Phase III Study of Vinflunine Plus Methotrexate Versus Methotrexate Alone in Patients With Head and Neck Cancer Completed NCT02347332 Phase 3 Vinflunine;Methotrexate
30 LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy Completed NCT01345682 Phase 3 Afatinib;Methotrexate
31 Very Intense Radiotherapy-Chemotherapy Regimen in Advanced HNSCC Completed NCT00162708 Phase 2, Phase 3 CDDP, 5 Fu
32 TRACE: Tirapazamine-Radiation And Cisplatin Evaluation Completed NCT00174837 Phase 3 Tirapazamine;Cisplatin
33 Post-operative Concurrent Chemo-radiotherapy Versus Post-operative Radiotherapy for Cancer of the Head and Neck Completed NCT00193895 Phase 3 Carboplatin
34 Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery Completed NCT00424255 Phase 3 Lapatinib
35 Induction Chemotherapy Comparing Taxotere® Cisplatin and 5-Fluorouracil (TPF) With Standard Cisplatin and 5-Fluorouracil (PF) Followed by Chemoradiation in Locally Advanced Head and Neck Cancer Completed NCT00273546 Phase 3 XRP6976 (Docetaxel/Taxotere)
36 Isotretinoin, Interferon Alfa, and Vitamin E in Treating Patients With Stage III or Stage IV Head and Neck Cancer Completed NCT00054561 Phase 3 isotretinoin
37 Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer Completed NCT00003592 Phase 3 methotrexate;paclitaxel
38 Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer That Has Been Removed During Surgery Completed NCT00002670 Phase 3 chemotherapy;cisplatin
39 Radiation Therapy and Cisplatin or Panitumumab in Treating Patients With Locally Advanced Stage III or Stage IV Head and Neck Cancer Completed NCT00820248 Phase 3 cisplatin
40 Biafine Cream to Reduce Side Effects of Radiation Therapy in Patients Receiving Treatment for Advanced Head and Neck Cancer Completed NCT00006481 Phase 3 Biafine cream
41 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00003888 Phase 3 cisplatin;docetaxel;fluorouracil
42 Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT Completed NCT01931150 Phase 3 Topical Dapsone 5% Gel;oral antibiotics
43 Low-level Laser Therapy to Prevent Oral Mucositis in Head and Neck Patients Completed NCT01439724 Phase 3
44 Double Blind Phase III Trial of Effects of Low Dose 13-Cisretinoic Acid on Prevention of Second Primaries in Stages I-II Head and Neck Cancer Completed NCT03370367 Phase 3 13-cis retinoic acid
45 Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer Completed NCT01434394 Phase 2, Phase 3 Neo-adjuvant Erbitux-based chemotherapy
46 NIMRAD (A Randomised Placebo-controlled Trial of Synchronous NIMorazole Versus RADiotherapy Alone in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Not Suitable for Synchronous Chemotherapy or Cetuximab) Recruiting NCT01950689 Phase 3 Nimorazole
47 Changes in Body Composition After EPA Supplementation in Head and Neck Patients Recruiting NCT02715596 Phase 3
48 Randomized Multicentric Comparative Study Between a Conventional and an Intensive Follow up Strategy After Treatment of a Head and Neck Squamous Cell Carcinoma Recruiting NCT03519048 Phase 3
49 A Study of Atezolizumab (Anti−Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck Recruiting NCT03452137 Phase 3 Atezolizumab;Placebo
50 A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck Recruiting NCT03576417 Phase 3 Cisplatin;Nivolumab

Search NIH Clinical Center for Squamous Cell Carcinoma, Head and Neck

Genetic Tests for Squamous Cell Carcinoma, Head and Neck

Genetic tests related to Squamous Cell Carcinoma, Head and Neck:

# Genetic test Affiliating Genes
1 Squamous Cell Carcinoma of the Head and Neck 30 ING1 TNFRSF10B

Anatomical Context for Squamous Cell Carcinoma, Head and Neck

MalaCards organs/tissues related to Squamous Cell Carcinoma, Head and Neck:

42
Skin, Lymph Node, Salivary Gland, T Cells, Testes, Prostate, Thyroid

Publications for Squamous Cell Carcinoma, Head and Neck

Articles related to Squamous Cell Carcinoma, Head and Neck:

(show top 50) (show all 1792)
# Title Authors Year
1
Wnt3a promotes radioresistance via autophagy in squamous cell carcinoma of the head and neck. ( 31111621 )
2019
2
Real-world systemic therapy treatment patterns for squamous cell carcinoma of the head and neck in Canada. ( 31043823 )
2019
3
A phase I study of afatinib in combination with postoperative radiation therapy with and without weekly docetaxel in intermediate- and high-risk patients with resected squamous cell carcinoma of the head and neck. ( 31082494 )
2019
4
Survival Outcomes for Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck. ( 31091995 )
2019
5
A Q-TWiST Analysis Comparing Nivolumab and Therapy of Investigator's Choice in Patients with Recurrent/Metastatic Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck. ( 30972702 )
2019
6
Number of nodal metastases and prognosis in metastatic cutaneous squamous cell carcinoma of the head and neck. ( 30974495 )
2019
7
Potential role of cyclin-dependent kinase 4/6 inhibitors in the treatment of squamous cell carcinoma of the head and neck. ( 30986809 )
2019
8
Immunotherapy in recurrent and or metastatic squamous cell carcinoma of the head and neck. ( 30893146 )
2019
9
Economic burden of chemotherapy-treated recurrent and/or metastatic squamous cell carcinoma of the head and neck in france: real world data from the permanent sample of national health insurance beneficiairies. ( 30895832 )
2019
10
Phase 1 Study Evaluating the Association of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib and Cetuximab in Recurrent/Metastatic p16-Negative Squamous Cell Carcinoma of the Head and Neck. ( 30941307 )
2019
11
HPV Status and Survival in Non-Oropharyngeal Squamous Cell Carcinoma of the Head and Neck. ( 30952732 )
2019
12
Concurrent chemoradiotherapy with weekly versus triweekly cisplatin in locally advanced squamous cell carcinoma of the head and neck: A comparative analysis. ( 30835900 )
2019
13
Sentinel lymph node biopsy for high-risk cutaneous squamous cell carcinoma of the head and neck. ( 30843617 )
2019
14
Staging of oropharyngeal squamous cell carcinoma of the head and neck: Prognostic features and power of the 8th edition of the UICC staging manual. ( 30857877 )
2019
15
AP001056.1, A Prognosis-Related Enhancer RNA in Squamous Cell Carcinoma of the Head and Neck. ( 30862109 )
2019
16
Sustained complete response to erlotinib in squamous cell carcinoma of the head and neck: A case report. ( 30863760 )
2019
17
Adult Comorbidity Evaluation-27 as a predictor of postoperative complications, two-year mortality, duration of hospital stay, and readmission within 30 days in patients with squamous cell carcinoma of the head and neck. ( 30890290 )
2019
18
Cervical metastasis of squamous cell carcinoma of the head and neck. Therapeutic options. ( 30768062 )
2019
19
CCL18 promotes the metastasis of squamous cell carcinoma of the head and neck through MTDH-NF-κB signalling pathway. ( 30768878 )
2019
20
Successful treatment with trastuzumab in HER2-positive squamous cell carcinoma of the head and neck. ( 30773349 )
2019
21
Oligometastatic squamous cell carcinoma of the head and neck treated with stereotactic body ablative radiotherapy: Single-institution outcomes. ( 30788878 )
2019
22
Clinical outcomes of platinum-based chemotherapy plus cetuximab for recurrent or metastatic squamous cell carcinoma of the head and neck: comparison between platinum-sensitive and platinum-resistant patients. ( 30794080 )
2019
23
Association of Disease Recurrence With Survival Outcomes in Patients With Cutaneous Squamous Cell Carcinoma of the Head and Neck Treated With Multimodality Therapy. ( 30810715 )
2019
24
Comparison of second-line treatments of recurrent and/or metastatic squamous cell carcinoma of the head and neck. ( 30669875 )
2019
25
Outcomes following radiation for cutaneous squamous cell carcinoma of the head and neck: Associations between immune suppression and recurrence. ( 30697925 )
2019
26
A Multicenter Phase II Trial of Docetaxel, Cisplatin, and Cetuximab (TPEx) Followed by Cetuximab and Concurrent Radiotherapy for Patients With Local Advanced Squamous Cell Carcinoma of the Head and Neck (CSPOR HN01: ECRIPS Study). ( 30723701 )
2019
27
3-weekly or weekly cisplatin concurrently with radiotherapy for patients with squamous cell carcinoma of the head and neck - a multicentre, retrospective analysis. ( 30744643 )
2019
28
Combined Aurora kinase A (AURKA) and WEE1 inhibition demonstrates synergistic antitumor effect in squamous cell carcinoma of the head and neck. ( 30755439 )
2019
29
Prognostic factors in recurrent or metastatic squamous cell carcinoma of the head and neck. ( 30652392 )
2019
30
A critical analysis of the prognostic performance of the 8th edition American Joint Committee on Cancer staging for metastatic cutaneous squamous cell carcinoma of the head and neck. ( 30659690 )
2019
31
Is there a patient population with squamous cell carcinoma of the head and neck region who might benefit from de-intensification of postoperative radiotherapy? : A monocentric retrospective analysis of a previously defined low-risk patient population treated with standard-of-care radiotherapy. ( 30610355 )
2019
32
Cetuximab-associated pulmonary toxicity in concurrent chemoradiation for the treatment of a squamous cell carcinoma of the head and neck. ( 30614125 )
2019
33
Treatment patterns and outcomes among patients with recurrent/metastatic squamous cell carcinoma of the head and neck. ( 30511880 )
2019
34
Real-world treatment patterns and outcomes of patients with stage IV squamous cell carcinoma of the head and neck. ( 30426780 )
2019
35
Natural history of untreated squamous cell carcinoma of the head and neck. ( 30444304 )
2019
36
JAAD Game Changers: Multivariate analysis of potential risk factors for lymph node metastasis in patients with cutaneous squamous cell carcinoma of the head and neck. ( 30447320 )
2019
37
JAAD Game Changers: Multivariate analysis of potential risk factors for lymph node metastasis in patients with cutaneous squamous cell carcinoma of the head and neck. ( 30389358 )
2019
38
Cisplatin Every 3 Weeks Versus Weekly With Definitive Concurrent Radiotherapy for Squamous Cell Carcinoma of the Head and Neck. ( 30239887 )
2019
39
Effect of ESA as a modifier of radiotherapy in curative intended treatment of squamous cell carcinoma of the head and neck (HNSCC). ( 30249347 )
2019
40
Measurement of circulating tumor cells in squamous cell carcinoma of the head and neck and patient outcomes. ( 30084036 )
2019
41
A Limited Immunohistochemical Panel to Distinguish Basal Cell Carcinoma of Cutaneous Origin From Basaloid Squamous Cell Carcinoma of the Head and Neck. ( 27438511 )
2018
42
Predictive Value of Cetuximab-Induced Skin Toxicity in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NECK. ( 30619755 )
2018
43
Association of Adjuvant Radiation Therapy With Survival in Patients With Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck. ( 30570645 )
2018
44
Squamous cell carcinoma of the head and neck in children. ( 30579067 )
2018
45
Salvage Surgery for Recurrence after Radiotherapy for Squamous Cell Carcinoma of the Head and Neck. ( 30526317 )
2018
46
Use of 18F-FDG PET/CT Imaging for Radiotherapy Target Volume Delineation after Induction Chemotherapy and for Prognosis of Locally Advanced Squamous Cell Carcinoma of the Head and Neck. ( 30544718 )
2018
47
Pattern of planned systemic therapy usage in newly diagnosed, nonmetastatic squamous cell carcinoma of the head and neck in a commercially insured population in the United States. ( 30421818 )
2018
48
Meta-analysis of clinical trials comparing the efficacy and safety of liposomal cisplatin versus conventional nonliposomal cisplatin in nonsmall cell lung cancer (NSCLC) and squamous cell carcinoma of the head and neck (SCCHN). ( 30431590 )
2018
49
Associations Between Poor Oral Health and Risk of Squamous Cell Carcinoma of the Head and Neck: A Meta-Analysis of Observational Studies. ( 30448433 )
2018
50
Window Studies in Squamous Cell Carcinoma of the Head and Neck: Values and Limits. ( 30367283 )
2018

Variations for Squamous Cell Carcinoma, Head and Neck

UniProtKB/Swiss-Prot genetic disease variations for Squamous Cell Carcinoma, Head and Neck:

76
# Symbol AA change Variation ID SNP ID
1 ING1 p.Ala335Asp VAR_017420
2 ING1 p.Cys358Ser VAR_017421
3 ING1 p.Asn359Ser VAR_017422
4 ING3 p.Asp20Gly VAR_021263
5 PTEN p.Ala121Gly VAR_018103 rs121909237

ClinVar genetic disease variations for Squamous Cell Carcinoma, Head and Neck:

6 (show top 50) (show all 691)
# Gene Variation Type Significance SNP ID Assembly Location
1 TNFRSF10B TNFRSF10B, 2-BP INS insertion Pathogenic
2 PTEN NM_000314.4(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 GRCh37 Chromosome 10, 89692905: 89692905
3 PTEN NM_000314.4(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 GRCh38 Chromosome 10, 87933148: 87933148
4 PTEN NM_000314.6(PTEN): c.362C> G (p.Ala121Gly) single nucleotide variant Pathogenic rs121909237 GRCh37 Chromosome 10, 89692878: 89692878
5 PTEN NM_000314.6(PTEN): c.362C> G (p.Ala121Gly) single nucleotide variant Pathogenic rs121909237 GRCh38 Chromosome 10, 87933121: 87933121
6 ING1 NM_198217.2(ING1): c.512G> C (p.Cys171Ser) single nucleotide variant Pathogenic rs121909250 GRCh37 Chromosome 13, 111372083: 111372083
7 ING1 NM_198217.2(ING1): c.512G> C (p.Cys171Ser) single nucleotide variant Pathogenic rs121909250 GRCh38 Chromosome 13, 110719736: 110719736
8 ING1 NM_198217.2(ING1): c.515A> G (p.Asn172Ser) single nucleotide variant Pathogenic rs121909251 GRCh37 Chromosome 13, 111372086: 111372086
9 ING1 NM_198217.2(ING1): c.515A> G (p.Asn172Ser) single nucleotide variant Pathogenic rs121909251 GRCh38 Chromosome 13, 110719739: 110719739
10 ING1 NM_198217.2(ING1): c.443C> A (p.Ala148Asp) single nucleotide variant Pathogenic rs121909252 GRCh37 Chromosome 13, 111372014: 111372014
11 ING1 NM_198217.2(ING1): c.443C> A (p.Ala148Asp) single nucleotide variant Pathogenic rs121909252 GRCh38 Chromosome 13, 110719667: 110719667
12 MAP2K2 NM_030662.3(MAP2K2): c.169T> G (p.Phe57Val) single nucleotide variant Pathogenic rs121434498 GRCh37 Chromosome 19, 4117551: 4117551
13 MAP2K2 NM_030662.3(MAP2K2): c.169T> G (p.Phe57Val) single nucleotide variant Pathogenic rs121434498 GRCh38 Chromosome 19, 4117553: 4117553
14 SMAD4 NM_005359.5(SMAD4): c.1081C> T (p.Arg361Cys) single nucleotide variant Pathogenic rs80338963 GRCh37 Chromosome 18, 48591918: 48591918
15 SMAD4 NM_005359.5(SMAD4): c.1081C> T (p.Arg361Cys) single nucleotide variant Pathogenic rs80338963 GRCh38 Chromosome 18, 51065548: 51065548
16 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
17 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh38 Chromosome 17, 7674221: 7674221
18 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
19 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 GRCh38 Chromosome 17, 7674230: 7674230
20 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic rs121912655 GRCh37 Chromosome 17, 7577556: 7577556
21 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic rs121912655 GRCh38 Chromosome 17, 7674238: 7674238
22 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 GRCh37 Chromosome 17, 7577547: 7577547
23 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 GRCh38 Chromosome 17, 7674229: 7674229
24 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
25 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh38 Chromosome 17, 7674220: 7674220
26 TP53 NM_000546.5(TP53): c.814G> T (p.Val272Leu) single nucleotide variant Likely pathogenic rs121912657 GRCh37 Chromosome 17, 7577124: 7577124
27 TP53 NM_000546.5(TP53): c.814G> T (p.Val272Leu) single nucleotide variant Likely pathogenic rs121912657 GRCh38 Chromosome 17, 7673806: 7673806
28 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
29 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh38 Chromosome 17, 7674241: 7674241
30 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Conflicting interpretations of pathogenicity rs28934574 GRCh37 Chromosome 17, 7577094: 7577094
31 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Conflicting interpretations of pathogenicity rs28934574 GRCh38 Chromosome 17, 7673776: 7673776
32 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
33 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 GRCh38 Chromosome 17, 7674230: 7674230
34 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
35 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh38 Chromosome 17, 7673802: 7673802
36 TP53 NM_000546.5(TP53): c.839G> C (p.Arg280Thr) single nucleotide variant Uncertain significance rs121912660 GRCh37 Chromosome 17, 7577099: 7577099
37 TP53 NM_000546.5(TP53): c.839G> C (p.Arg280Thr) single nucleotide variant Uncertain significance rs121912660 GRCh38 Chromosome 17, 7673781: 7673781
38 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
39 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Likely pathogenic rs28934874 GRCh38 Chromosome 17, 7675161: 7675161
40 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
41 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh38 Chromosome 17, 7675161: 7675161
42 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
43 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 GRCh38 Chromosome 17, 7674872: 7674872
44 HRAS NM_176795.4(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
45 HRAS NM_176795.4(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
46 HRAS NM_005343.2(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
47 HRAS NM_005343.2(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh38 Chromosome 11, 534288: 534288
48 HRAS NM_005343.4(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
49 HRAS NM_005343.4(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh38 Chromosome 11, 534286: 534286
50 HRAS NM_005343.2(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289

Cosmic variations for Squamous Cell Carcinoma, Head and Neck:

9 (show top 50) (show all 4162)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM4605053 ZNF804B upper aerodigestive tract,head neck,carcinoma,squamous cell carcinoma c.3029A>G p.H1010R 7:89336011-89336011 0
2 COSM4604788 ZNF804B upper aerodigestive tract,head neck,carcinoma,squamous cell carcinoma c.226T>A p.S76T 7:89218272-89218272 0
3 COSM4605083 ZNF804B upper aerodigestive tract,head neck,carcinoma,squamous cell carcinoma c.3076C>T p.L1026F 7:89336058-89336058 0
4 COSM3724309 ZNF536 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.1935G>C p.Q645H 19:30445497-30445497 0
5 COSM4604943 ZNF521 upper aerodigestive tract,head neck,carcinoma,squamous cell carcinoma c.2725C>A p.H909N 18:25225193-25225193 0
6 COSM4606119 ZNF521 upper aerodigestive tract,head neck,carcinoma,squamous cell carcinoma c.919G>C p.E307Q 18:25226999-25226999 0
7 COSM4604999 ZNF521 upper aerodigestive tract,head neck,carcinoma,squamous cell carcinoma c.2847G>A p.M949I 18:25225071-25225071 0
8 COSM4604604 ZNF521 upper aerodigestive tract,head neck,carcinoma,squamous cell carcinoma c.1905C>G p.I635M 18:25226013-25226013 0
9 COSM4605179 ZNF521 upper aerodigestive tract,head neck,carcinoma,squamous cell carcinoma c.3448G>A p.E1150K 18:25224470-25224470 0
10 COSM4604099 ZNF521 upper aerodigestive tract,head neck,carcinoma,squamous cell carcinoma c.1142G>C p.R381P 18:25226776-25226776 0
11 COSM4605994 ZNF521 upper aerodigestive tract,head neck,carcinoma,squamous cell carcinoma c.838G>A p.A280T 18:25227080-25227080 0
12 COSM4604966 ZNF521 upper aerodigestive tract,head neck,carcinoma,squamous cell carcinoma c.2768C>A p.A923D 18:25225150-25225150 0
13 COSM4606086 ZIC1 upper aerodigestive tract,head neck,carcinoma,squamous cell carcinoma c.903C>A p.P301P 3:147411015-147411015 0
14 COSM4605820 ZFHX4 upper aerodigestive tract,head neck,carcinoma,squamous cell carcinoma c.7154C>A p.S2385Y 8:76854075-76854075 0
15 COSM2876115 ZFHX4 upper aerodigestive tract,head neck,carcinoma,squamous cell carcinoma c.2777G>A p.S926N 8:76707732-76707732 0
16 COSM4605385 ZFHX4 upper aerodigestive tract,head neck,carcinoma,squamous cell carcinoma c.4604T>A p.L1535H 8:76851525-76851525 0
17 COSM4605506 ZFHX4 upper aerodigestive tract,head neck,carcinoma,squamous cell carcinoma c.5134C>A p.Q1712K 8:76852055-76852055 0
18 COSM4605529 ZFHX4 upper aerodigestive tract,head neck,carcinoma,squamous cell carcinoma c.5278G>T p.A1760S 8:76852199-76852199 0
19 COSM4593669 ZFHX4 upper aerodigestive tract,head neck,carcinoma,squamous cell carcinoma c.7250A>C p.D2417A 8:76854171-76854171 0
20 COSM4605800 ZFHX4 upper aerodigestive tract,head neck,carcinoma,squamous cell carcinoma c.7051G>C p.D2351H 8:76853972-76853972 0
21 COSM1553134 ZFHX4 upper aerodigestive tract,head neck,carcinoma,squamous cell carcinoma c.8887G>T p.G2963W 8:76855808-76855808 0
22 COSM1314208 ZFHX4 upper aerodigestive tract,head neck,carcinoma,squamous cell carcinoma c.5044C>G p.Q1682E 8:76851965-76851965 0
23 COSM4604655 ZFHX4 upper aerodigestive tract,head neck,carcinoma,squamous cell carcinoma c.2006A>C p.E669A 8:76706094-76706094 0
24 COSM4605460 ZFHX4 upper aerodigestive tract,head neck,carcinoma,squamous cell carcinoma c.4944G>T p.G1648G 8:76851865-76851865 0
25 COSM4605149 ZFHX4 upper aerodigestive tract,head neck,carcinoma,squamous cell carcinoma c.3454G>C p.E1152Q 8:76842714-76842714 0
26 COSM4605188 ZFHX4 upper aerodigestive tract,head neck,carcinoma,squamous cell carcinoma c.3652C>G p.Q1218E 8:76849518-76849518 0
27 COSM4606003 ZFHX4 upper aerodigestive tract,head neck,carcinoma,squamous cell carcinoma c.843C>A p.F281L 8:76704931-76704931 0
28 COSM6845145 ZFHX3 salivary gland,NS,carcinoma,squamous cell carcinoma c.8617G>A p.E2873K 16:72794065-72794065 0
29 COSM6970691 ZFHX3 upper aerodigestive tract,oropharynx,carcinoma,squamous cell carcinoma c.3676C>T p.P1226S 16:72811765-72811765 0
30 COSM6927812 ZFHX3 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.4946C>T p.S1649F 16:72797736-72797736 0
31 COSM6961423 ZFHX3 upper aerodigestive tract,oropharynx,carcinoma,squamous cell carcinoma c.10897C>T p.P3633S 16:72787379-72787379 0
32 COSM4604606 ZEB2 upper aerodigestive tract,head neck,carcinoma,squamous cell carcinoma c.191G>A p.S64N 2:144429909-144429909 0
33 COSM4604806 ZEB2 upper aerodigestive tract,head neck,carcinoma,squamous cell carcinoma c.2314G>T p.V772F 2:144398873-144398873 0
34 COSM4604336 YTHDC1 upper aerodigestive tract,head neck,carcinoma,squamous cell carcinoma c.1417A>G p.I473V 4:68324156-68324156 0
35 COSM4604255 YTHDC1 upper aerodigestive tract,head neck,carcinoma,squamous cell carcinoma c.131-2A>C p.? 4:68337902-68337902 0
36 COSM6976115 YES1 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.1288C>T p.Q430* 18:736811-736811 0
37 COSM4604315 XRCC6 upper aerodigestive tract,head neck,carcinoma,squamous cell carcinoma c.1383G>A p.K461K 22:41656994-41656994 0
38 COSM4604130 XRCC6 upper aerodigestive tract,head neck,carcinoma,squamous cell carcinoma c.1177G>T p.E393* 22:41653576-41653576 0
39 COSM4604204 XRCC6 upper aerodigestive tract,head neck,carcinoma,squamous cell carcinoma c.1255G>A p.E419K 22:41653654-41653654 0
40 COSM6914703 XPO1 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.619C>G p.Q207E 2:61498885-61498885 0
41 COSM4604219 WT1 upper aerodigestive tract,head neck,carcinoma,squamous cell carcinoma c.1071C>G p.F357L 11:32392730-32392730 0
42 COSM2958661 WRN upper aerodigestive tract,head neck,carcinoma,squamous cell carcinoma c.2790G>T p.M930I 8:31124965-31124965 0
43 COSM4605244 WRN upper aerodigestive tract,head neck,carcinoma,squamous cell carcinoma c.3832G>C p.E1278Q 8:31157380-31157380 0
44 COSM4606286 WRN upper aerodigestive tract,head neck,carcinoma,squamous cell carcinoma c.1898+3G>C p.? 8:31091901-31091901 0
45 COSM1659071 WASF2 salivary gland,mouth floor,carcinoma,NS c.15G>T p.T5T 1:27428876-27428876 0
46 COSM4604693 VWA5A upper aerodigestive tract,head neck,carcinoma,squamous cell carcinoma c.2075G>T p.G692V 11:124142493-124142493 0
47 COSM3788274 VPS41 upper aerodigestive tract,head neck,carcinoma,squamous cell carcinoma c.2145C>A p.N715K 7:38742099-38742099 0
48 COSM4604730 VPS41 upper aerodigestive tract,head neck,carcinoma,squamous cell carcinoma c.2122C>T p.P708S 7:38743402-38743402 0
49 COSM14356 VHL skin,head neck,carcinoma,squamous cell carcinoma c.394C>T p.Q132* 3:10146567-10146567 0
50 COSM30228 VHL skin,head neck,carcinoma,squamous cell carcinoma c.337C>T p.R113* 3:10142184-10142184 0

Copy number variations for Squamous Cell Carcinoma, Head and Neck from CNVD:

7 (show all 42)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 33952 1 50700000 61300000 Amplification head and neck squamous cell carcinoma
2 71135 12 67700000 71500000 Amplification head and neck squamous cell carcinoma
3 78639 13 55300000 73300000 Amplification head and neck squamous cell carcinoma
4 90904 15 25700000 28100000 Amplification head and neck squamous cell carcinoma
5 93784 15 59100000 59300000 Copy number MET head and neck squamous cell carcinoma
6 118006 17 7505821 7531588 LOH TP53 head and neck squamous cell carcinoma
7 119192 18 1 7100000 Amplification head and neck squamous cell carcinoma
8 119790 18 17200000 19000000 Amplification head and neck squamous cell carcinoma
9 166134 3 1 87900000 Loss head and neck squamous cell carcinoma
10 167635 3 121900000 167600000 Gain head and neck squamous cell carcinoma
11 169556 3 142800000 148900000 Amplification head and neck squamous cell carcinoma
12 171486 3 168801287 168851758 Amplification EVI1 head and neck squamous cell carcinoma
13 171495 3 168867391 169381563 Amplification MDS1 head and neck squamous cell carcinoma
14 172487 3 182700000 187900000 Amplification RFC4 head and neck squamous cell carcinoma
15 174746 12 7773277 7793336 Deletion DLEC head and neck squamous cell carcinoma
16 179443 3 91000000 121900000 Gain head and neck squamous cell carcinoma
17 179973 4 1 50400000 Loss head and neck squamous cell carcinoma
18 204736 6 114600000 171115067 Gain head and neck squamous cell carcinoma
19 217049 7 1 159138663 Copy number head and neck squamous cell carcinoma
20 225369 7 45400000 54000000 Gain EGFR head and neck squamous cell carcinoma
21 225383 7 45400000 54000000 Amplification EGFR head and neck squamous cell carcinoma
22 225403 7 45400000 54000000 Copy number EGFR head and neck squamous cell carcinoma
23 225404 7 45400000 54000000 Copy number EGFR head and neck squamous cell carcinoma
24 225408 7 45400000 54000000 Deletion or amplific ation EGFR head and neck squamous cell carcinoma
25 225413 7 45400000 58000000 Amplification head and neck squamous cell carcinoma
26 226532 7 58000000 59900000 Amplification head and neck squamous cell carcinoma
27 232747 8 119200000 122500000 Gain MYC head and neck squamous cell carcinoma
28 233769 8 127300000 139900000 Gain KHDRBS3 head and neck squamous cell carcinoma
29 234876 8 139900000 146364022 Gain FAK head and neck squamous cell carcinoma
30 234895 8 139900000 146364022 Gain PTP4A3 head and neck squamous cell carcinoma
31 238011 8 28800000 45600000 Amplification head and neck squamous cell carcinoma
32 239988 8 43100000 45600000 Amplification head and neck squamous cell carcinoma
33 240109 8 45600000 146364022 Gain GAA1 head and neck squamous cell carcinoma
34 241899 8 68000000 70500000 Amplification head and neck squamous cell carcinoma
35 243677 8 86900000 101600000 Amplification RUNX1T1 head and neck squamous cell carcinoma
36 249984 9 19900000 25500000 Deletion CDKN2A head and neck squamous cell carcinoma
37 300518 11 95351087 95715992 Methylation MAML2 head and neck squamous cell carcinoma
38 300530 12 123374913 123617963 Methylation NCOR2 head and neck squamous cell carcinoma
39 300892 14 72672931 72756862 Methylation PSEN1 head and neck squamous cell carcinoma
40 300893 14 72811670 72995039 Methylation NUMB head and neck squamous cell carcinoma
41 302931 19 45863651 45888396 Methylation NUMBL head and neck squamous cell carcinoma
42 303261 20 10566331 10602694 Methylation JAG1 head and neck squamous cell carcinoma

Expression for Squamous Cell Carcinoma, Head and Neck

LifeMap Discovery
Genes differentially expressed in tissues of Squamous Cell Carcinoma, Head and Neck patients vs. healthy controls: 35 (show all 15)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 MMP1 matrix metallopeptidase 1 Head Mesenchyme + 5.25 0.000
2 TMPRSS11B transmembrane protease, serine 11B Head Mesenchyme - 4.81 0.000
3 CRISP3 cysteine-rich secretory protein 3 Head Mesenchyme - 4.48 0.000
4 MAL mal, T-cell differentiation protein Head Mesenchyme - 4.39 0.000
5 INHBA inhibin, beta A Head Mesenchyme + 4.13 0.000
6 CRNN cornulin Head Mesenchyme - 4.00 0.000
7 KRT17 keratin 17, type I Head Mesenchyme + 3.94 0.000
8 KRT4 keratin 4, type II Head Mesenchyme - 3.41 0.000
9 PTHLH parathyroid hormone-like hormone Head Mesenchyme + 3.36 0.000
10 CTHRC1 collagen triple helix repeat containing 1 Head Mesenchyme + 3.32 0.000
11 CLCA4 chloride channel accessory 4 Head Mesenchyme - 3.31 0.000
12 WDR72 WD repeat domain 72 Head Mesenchyme + 3.23 0.000
13 MMP10 matrix metallopeptidase 10 Head Mesenchyme + 3.14 0.001
14 TGM3 transglutaminase 3 Head Mesenchyme - 3.08 0.000
15 GBP1 guanylate binding protein 1, interferon-inducible Head Mesenchyme + 3.06 0.000
Search GEO for disease gene expression data for Squamous Cell Carcinoma, Head and Neck.

Pathways for Squamous Cell Carcinoma, Head and Neck

Pathways related to Squamous Cell Carcinoma, Head and Neck according to GeneCards Suite gene sharing:

(show top 50) (show all 145)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.97 AKT1 BRAF FGFR3 GNAS HRAS MAP2K2
2
Show member pathways
13.79 AKT1 BRAF FGFR3 GNAS HRAS MAP2K2
3
Show member pathways
13.66 AKT1 BRAF FGFR3 GNAS HRAS MAP2K2
4
Show member pathways
13.5 AKT1 FGFR3 GNAS HRAS PTEN TNFRSF10B
5
Show member pathways
13.49 AKT1 BRAF GNAS HRAS MAP2K2 PIK3CA
6
Show member pathways
13.46 AKT1 BRAF FGFR3 HRAS MAP2K2 PIK3CA
7
Show member pathways
13.32 AKT1 BRAF GNAS HRAS MAP2K2 PTEN
8
Show member pathways
13.2 AKT1 BRAF FGFR3 GNAS HRAS MAP2K2
9
Show member pathways
13.12 AKT1 BRAF GNAS HRAS MAP2K2 TP53
10
Show member pathways
13.11 AKT1 FGFR3 GNAS HRAS MAP2K2 PIK3CA
11
Show member pathways
13.1 AKT1 GNAS HRAS MAP2K2 PIK3CA PTEN
12
Show member pathways
13.08 AKT1 HRAS MAP2K2 PIK3CA PTEN TNFRSF10B
13
Show member pathways
13.06 AKT1 BRAF GNAS HRAS MAP2K2 PIK3CA
14
Show member pathways
13.02 AKT1 BRAF HRAS MAP2K2 PIK3CA PTEN
15
Show member pathways
13.02 AKT1 BRAF HRAS MAP2K2 PIK3CA PTEN
16
Show member pathways
12.99 AKT1 BRAF FGFR3 GNAS HRAS MAP2K2
17
Show member pathways
12.99 AKT1 BRAF HRAS MAP2K2 PIK3CA PTEN
18
Show member pathways
12.93 AKT1 HRAS MAP2K2 PIK3CA TNFRSF10B TP53
19
Show member pathways
12.9 AKT1 BRAF GNAS HRAS MAP2K2
20
Show member pathways
12.9 AKT1 BRAF HRAS MAP2K2 PIK3CA PTEN
21 12.89 AKT1 BRAF FGFR3 HRAS MAP2K2 TP53
22
Show member pathways
12.86 AKT1 BRAF FGFR3 GNAS HRAS MAP2K2
23
Show member pathways
12.85 AKT1 BRAF GNAS HRAS MAP2K2
24
Show member pathways
12.85 AKT1 FGFR3 HRAS PIK3CA PTEN TP53
25
Show member pathways
12.84 AKT1 BRAF HRAS MAP2K2 PIK3CA PTEN
26
Show member pathways
12.8 AKT1 GNAS HRAS MAP2K2 PIK3CA PTEN
27
Show member pathways
12.79 AKT1 BRAF HRAS MAP2K2 TP53
28
Show member pathways
12.78 AKT1 BRAF GNAS HRAS MAP2K2
29 12.75 BRAF FGFR3 HRAS MAP2K2 PIK3CA
30
Show member pathways
12.74 AKT1 BRAF HRAS MAP2K2 PIK3CA TP53
31
Show member pathways
12.72 AKT1 HRAS MAP2K2 PIK3CA TNFRSF10B
32
Show member pathways
12.72 AKT1 BRAF HRAS MAP2K2 NFE2L2 PIK3CA
33
Show member pathways
12.71 AKT1 HRAS MAP2K2 PIK3CA PTEN
34
Show member pathways
12.71 AKT1 BRAF FGFR3 GNAS HRAS MAP2K2
35
Show member pathways
12.69 AKT1 GNAS HRAS MAP2K2 PIK3CA
36
Show member pathways
12.66 AKT1 BRAF HRAS MAP2K2 PIK3CA SMAD4
37
Show member pathways
12.65 AKT1 HRAS MAP2K2 PIK3CA PTEN
38
Show member pathways
12.64 AKT1 HRAS MAP2K2 PIK3CA
39
Show member pathways
12.64 BRAF HRAS MAP2K2 PIK3CA TNFRSF10B
40
Show member pathways
12.61 AKT1 HRAS MAP2K2 PIK3CA PTEN
41
Show member pathways
12.59 AKT1 FGFR3 HRAS MAP2K2 PIK3CA TP53
42
Show member pathways
12.57 AKT1 FGFR3 HRAS MAP2K2 PIK3CA
43
Show member pathways
12.54 AKT1 GNAS HRAS MAP2K2 PIK3CA
44
Show member pathways
12.53 AKT1 BRAF HRAS MAP2K2 PIK3CA
45
Show member pathways
12.53 AKT1 HRAS MAP2K2 PIK3CA PTEN TP53
46
Show member pathways
12.52 AKT1 HRAS PIK3CA TP53
47
Show member pathways
12.52 AKT1 BRAF HRAS MAP2K2 PIK3CA PTEN
48
Show member pathways
12.51 AKT1 BRAF HRAS MAP2K2
49
Show member pathways
12.51 AKT1 BRAF GNAS HRAS MAP2K2
50
Show member pathways
12.5 BRAF FGFR3 HRAS MAP2K2 PIK3CA

GO Terms for Squamous Cell Carcinoma, Head and Neck

Cellular components related to Squamous Cell Carcinoma, Head and Neck according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 micro-ribonucleoprotein complex GO:0035068 9.02 H19 MIR205 MIR21 MIR210 MIR98

Biological processes related to Squamous Cell Carcinoma, Head and Neck according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.95 AKT1 ING1 MAP2K2 NFE2L2 SMAD4 TP53
2 negative regulation of gene expression GO:0010629 9.92 AKT1 HRAS MAP2K2 MIR21
3 cell proliferation GO:0008283 9.91 AKT1 HRAS PTEN SMAD4 TP53
4 MAPK cascade GO:0000165 9.88 BRAF FGFR3 HRAS MAP2K2
5 negative regulation of apoptotic process GO:0043066 9.83 AKT1 BRAF MIR21 PTEN TP53
6 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.79 AKT1 BRAF PIK3CA
7 negative regulation of ERK1 and ERK2 cascade GO:0070373 9.77 MIR21 PTEN SMAD4
8 cellular response to drug GO:0035690 9.73 BRAF NFE2L2 TP53
9 positive regulation of blood vessel endothelial cell migration GO:0043536 9.67 AKT1 MIR210 NFE2L2
10 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.65 BRAF FGFR3 HRAS MIR21 PTEN
11 negative regulation of macroautophagy GO:0016242 9.63 AKT1 PIK3CA
12 negative regulation of cell proliferation GO:0008285 9.63 HRAS ING1 MIR21 PTEN SMAD4 TP53
13 negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway GO:1902176 9.62 AKT1 NFE2L2
14 cellular response to hypoxia GO:0071456 9.62 AKT1 NFE2L2 PTEN TP53
15 anoikis GO:0043276 9.61 AKT1 PIK3CA
16 negative regulation of cell size GO:0045792 9.6 AKT1 PTEN
17 positive regulation of metalloendopeptidase activity GO:1904685 9.58 MIR205 MIR21
18 protein kinase B signaling GO:0043491 9.58 AKT1 PIK3CA PTEN
19 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.57 MAP2K2 TP53
20 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.55 MIR21 MIR210
21 regulation of axon regeneration GO:0048679 9.54 BRAF PTEN
22 cellular response to nerve growth factor stimulus GO:1990090 9.54 AKT1 BRAF PTEN
23 cellular response to decreased oxygen levels GO:0036294 9.46 AKT1 PTEN
24 positive regulation of apoptotic process GO:0043065 9.43 AKT1 ING3 MIR21 PTEN TNFRSF10B TP53
25 positive regulation of gene expression GO:0010628 9.17 AKT1 BRAF HRAS MIR21 NFE2L2 PTEN
26 positive regulation of cell proliferation GO:0008284 10.03 AKT1 FGFR3 HRAS MIR21 PTEN
27 apoptotic process GO:0006915 10 AKT1 FGFR3 HRAS PTEN TNFRSF10B TP53

Molecular functions related to Squamous Cell Carcinoma, Head and Neck according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleotide binding GO:0000166 8.92 BRAF FGFR3 HRAS MAP2K2

Sources for Squamous Cell Carcinoma, Head and Neck

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....